Results 161 to 170 of about 19,474 (223)

Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression. [PDF]

Transl Oncol
De Ioris MA, Del Bufalo F, Quintarelli C, Bertaina V, Fabozzi F, Cefalo MG, Alessi I, Grimaldi C, Villani MF, D'Andrea ML, Stracuzzi A, Altini C, Malaspina C, Sinibaldi M, Di Cecca S, Iaffaldano L, Geraci C, Becilli M, De Angelis B, Crocoli A, Cassanelli G, Margaritora S, Mastronuzzi A, Locatelli F.   +23 more
europepmc   +1 more source

Study on the construction of algal-bacterial consortium comprising <i>Pantoea vagans</i> ZHS-1 and <i>Nostoc</i> sp. GD2 and its growth-promoting effect on rice. [PDF]

Microbiol Spectr
Dong J, Yue C, Tian S, Zhou X, Li S, Wang D, Wu Z, Yang M, Yang X, Wu L.   +9 more
europepmc   +1 more source

The role of personalised medicine in treating high-risk neuroblastoma in paediatric patients. [PDF]

Oncol Rev
Ammeti D, Curci D, Franzin M, Rabusin M, Zanchetta ME, Fabretto A.   +5 more
europepmc   +1 more source

Dual targeting of PDPN and GD2 enhances CAR T cell efficacy against glioblastoma and promotes durable tumor control. [PDF]

Mol Ther Oncol
Hübner J, Nerreter T.
europepmc   +1 more source

Comparative evidence on the independent contribution of granulocyte-macrophage colony-stimulating factor to anti-GD2 immunotherapy in neuroblastoma: a systematic review and gap analysis. [PDF]

Front Oncol
Wieczorek A, Mielecka-Jarmocik G, Synakiewicz A, Śladowska K, Kawalec P, Lode HN.   +5 more
europepmc   +1 more source

Targeted AAV gene therapy for neuroblastoma via direct capsid-antibody coupling. [PDF]

EMBO Mol Med
Luoni M, Parracino S, Giannelli SG, Morosi F, Ventura E, Di Pizio A, Muggeo S, Iannielli A, Sicardi S, Canu T, Russo T, Esposito A, Del Carro U, Pastorino F, Broccoli V.   +14 more
europepmc   +1 more source

Spatial and graded heterogeneity of GD2 expression in neuroblastoma revealed by whole-slide immunohistochemistry. [PDF]

Cancer Immunol Immunother
Fujikawa T, Inoue S, Nishimura A, Nakatani N, Yamamoto N, Hyodo T, Yoshida M, Hasegawa D, Nozu K, Tamura A.   +9 more
europepmc   +1 more source

GD2-targeted immunotherapy in pediatric bone sarcomas: a systematic review of emerging strategies and combination approaches. [PDF]

Front Immunol
Tirtei E, Poggi Longostrevi S, Bombaci S, Mercolini F, Pionelli MG, Asaftei SD, Fagioli F.   +6 more
europepmc   +1 more source

Overall survival after relapse in high-risk neuroblastoma: an adjusted indirect comparison of post-relapse dinutuximab beta, historical controls, and relapse after first-line dinutuximab beta maintenance. [PDF]

Front Oncol
Lode HN, Holko P, Wieczorek A, Śladowska K, Siebert N, Valteau-Couanet D, Garaventa A, Cañete A, Anderson J, Yaniv I, Ash S, Moreno L, Gray J, Luksch R, Laureys G, Owens C, Manzitti C, Troschke-Meurer S, Kawalec P, Ladenstein RL.   +19 more
europepmc   +1 more source

Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies. [PDF]

Exp Hematol Oncol
Mai Y, Wang Z, Wang J, Song M, Xiang T, He Y, Chang AH, Zhang Y.   +7 more
europepmc   +1 more source